EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The potential of smoke-free products to reduce harm for smokers: what does the toxicological evidence say?

Reinhard Niessner iD

Internal and Emergency Medicine · 2025

DOI: 10.1007/s11739-025-04093-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal and Emergency Medicine, 2025. Verfasst von Reinhard Niessner. Beteiligte Einrichtung: Chair of Analytical Chemistry and Water Chemistry, Institute of Hydrochemistry, Technical University of Munich, Lichtenbergstr. 4, Garching, 85748, G…. Hauptthemen laut MEDLINE: Smokers, Harm Reduction, Tobacco Products, Smoking. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There continues to be a high prevalence of smoking in many European countries. In Germany, for example, there are over 20 million smokers, most of whom exhibit little desire to quit. In other countries, the adoption of smoke-free products (SFPs), including e-cigarettes (ECs), heated tobacco products (HTPs), and oral nicotine pouches (NPs), is helping smokers to transition away from cigarettes. In Germany, debate about SFPs primarily focuses on their potential harms to non-smokers, particularly the underage population. This debate seems one-sided: raising concerns alone does not sufficiently inform the 20 million smokers about the comparative health risks of cigarettes and SFPs, an issue increasingly echoed by practitioners and researchers. Instead, the current discourse is dominated by misconceptions, as evidenced by surveys on smokers’ perceptions of the relative health risks of cigarettes and SFPs. Considering the gravity of the topic, it is essential to revisit the scientific facts. The growing evidence shows that SFPs, including ECs, HTPs, and NPs, expose users to significantly fewer numbers and lower concentrations of toxicants relative to combustible cigarettes. In vitro studies and biomarkers of harm in SFP users suggest that these lower emissions translate to reduced risks of harm. It is the nature of science that the evidence will never be complete, but the totality of data should be considered when discussing the correct handling of SFPs. At present, these data suggest that SFPs can play a useful role in curbing the individual and societal risks associated with smoking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SmokersHarm ReductionTobacco ProductsSmokingHumansElectronic Nicotine Delivery SystemsGermany

Stichwörter der Autor:innen

E-cigaretteHeated tobacco productOral nicotine productSmoke-free nicotine productToxicology

Autor:innen und Institutionen

  • Chair of Analytical Chemistry and Water Chemistry, Institute of Hydrochemistry, Technical University of Munich, Lichtenbergstr. 4, Garching, 85748, Garching, Germany. reinhard.niessner@mytum.de.

ORCID-Profile: Reinhard Niessner

Förderung

  • Technische Universität München

Zitieren

APA

Niessner, R. (2025). The potential of smoke-free products to reduce harm for smokers: what does the toxicological evidence say?. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-025-04093-0

Vancouver

Niessner R. The potential of smoke-free products to reduce harm for smokers: what does the toxicological evidence say?. Internal and Emergency Medicine. 2025. doi:10.1007/s11739-025-04093-0

BibTeX
@article{Niessner2025,
  author = {Niessner, Reinhard},
  title = {The potential of smoke-free products to reduce harm for smokers: what does the toxicological evidence say?},
  journal = {Internal and Emergency Medicine},
  year = {2025},
  doi = {10.1007/s11739-025-04093-0}
}
Kostenlos starten →